Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Lyra Therapeutics ( (LYRA) ).
On April 13, 2026, Lyra Therapeutics, Inc. agreed with RVAC Medicines (US), Inc. to terminate its sublease for about 23,704 rentable square feet at 880 Winter Street in Waltham, Massachusetts, originally signed on December 21, 2023. The sublease termination was effective as of March 31, 2026, with Lyra required to vacate the premises by May 31, 2026.
As part of the termination, Lyra will pay RVAC a $2.1 million termination fee, while its rent obligations ended on January 31, 2026. Upon Lyra completing its surrender obligations and making the termination payment, RVAC will return the company’s $600,501.32 letter of credit security deposit, adjusting Lyra’s near-term cash flows and real estate commitments.
The most recent analyst rating on (LYRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Underperform.
The score is driven primarily by very weak financial performance (minimal/declining revenue, persistent losses, negative free cash flow, and negative equity) alongside a strongly bearish technical trend. Corporate events add significant risk due to delisting and the pivot to a shell/strategic-alternatives posture, while valuation provides limited support given negative earnings and no dividend yield data.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for ear, nose and throat diseases, operating from leased and subleased office and laboratory space in the U.S. The company manages its real estate footprint as part of its broader effort to align operating costs with its development and commercialization plans.
Average Trading Volume: 72,090
Technical Sentiment Signal: Sell
Current Market Cap: $1.17M
See more data about LYRA stock on TipRanks’ Stock Analysis page.